Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $12.4 million.

  • Compass Therapeutics' Total Current Liabilities rose 179.99% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 179.99%. This contributed to the annual value of $8.9 million for FY2024, which is 13.75% up from last year.
  • Per Compass Therapeutics' latest filing, its Total Current Liabilities stood at $12.4 million for Q3 2025, which was down 10.43% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Total Current Liabilities ranged from a high of $14.9 million in Q1 2025 and a low of $3.9 million during Q1 2024.
  • Over the past 3 years, Compass Therapeutics' median Total Current Liabilities value was $9.5 million (recorded in 2024), while the average stood at $9.6 million.
  • In the last 5 years, Compass Therapeutics' Total Current Liabilities plummeted by 65.21% in 2024 and then spiked by 282.74% in 2025.
  • Over the past 3 years, Compass Therapeutics' Total Current Liabilities (Quarterly) stood at $7.8 million in 2023, then grew by 13.75% to $8.9 million in 2024, then spiked by 179.99% to $12.4 million in 2025.
  • Its Total Current Liabilities was $12.4 million in Q3 2025, compared to $13.9 million in Q2 2025 and $14.9 million in Q1 2025.